tradingkey.logo
tradingkey.logo
Search

MaxCyte Inc

MXCT
Add to Watchlist
1.040USD
-0.050-4.59%
Close 05/15, 16:00ETQuotes delayed by 15 min
111.41MMarket Cap
LossP/E TTM

More Details of MaxCyte Inc Company

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

MaxCyte Inc Info

Ticker SymbolMXCT
Company nameMaxCyte Inc
IPO dateMar 29, 2016
CEOMasoud (Maher)
Number of employees114
Security typeOrdinary Share
Fiscal year-endMar 29
Address9713 Key West Avenue,
CityROCKVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20850
Phone13015175556
Websitehttps://www.maxcyte.com/
Ticker SymbolMXCT
IPO dateMar 29, 2016
CEOMasoud (Maher)

Company Executives of MaxCyte Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
--
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
--
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
-171.43%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
--
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
82.92K
+51.93%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
--
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
39.89K
--
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Sandoval
Mr. David Sandoval
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
--
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
--
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
-171.43%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
--
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
82.92K
+51.93%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
--

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
By BusinessUSD
Name
Revenue
Proportion
Product sales
18.69M
56.59%
Product
18.69M
56.59%
Licenses
12.37M
37.45%
other
1.97M
5.95%
By RegionUSD
Name
Revenue
Proportion
Inside the United States
21.08M
63.82%
Outside the United States
11.95M
36.18%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product sales
18.69M
56.59%
Product
18.69M
56.59%
Licenses
12.37M
37.45%
other
1.97M
5.95%

Shareholding Stats

Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capricorn Fund Managers Ltd
7.65%
BlackRock Institutional Trust Company, N.A.
6.96%
River Global Investors LLP
5.13%
Vitruvian Partners LLP
4.71%
Vanguard Capital Management, LLC
3.72%
Other
71.83%
Shareholders
Shareholders
Proportion
Capricorn Fund Managers Ltd
7.65%
BlackRock Institutional Trust Company, N.A.
6.96%
River Global Investors LLP
5.13%
Vitruvian Partners LLP
4.71%
Vanguard Capital Management, LLC
3.72%
Other
71.83%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.60%
Investment Advisor/Hedge Fund
20.75%
Hedge Fund
8.15%
Private Equity
4.71%
Research Firm
3.93%
Individual Investor
1.37%
Venture Capital
0.32%
Pension Fund
0.21%
Bank and Trust
0.20%
Other
31.76%

Institutional Shareholding

Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
292
79.92M
74.61%
-18.93M
2025Q4
282
79.65M
74.66%
-13.91M
2025Q3
287
82.96M
77.85%
-17.02M
2025Q2
296
78.80M
73.92%
-18.62M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Capricorn Fund Managers Ltd
8.20M
7.67%
+8.20M
--
Jan 30, 2026
BlackRock Institutional Trust Company, N.A.
7.45M
6.98%
-585.24K
-7.28%
Dec 31, 2025
River Global Investors LLP
5.50M
5.14%
+2.24M
+68.99%
Oct 23, 2025
Vitruvian Partners LLP
5.04M
4.72%
--
--
Dec 31, 2025
Cadian Capital Management LP
3.68M
3.45%
-4.54M
-55.24%
Dec 31, 2025
Mudita Advisors LLP
3.37M
3.15%
--
--
Dec 31, 2025
Morgan Stanley & Co. LLC
3.03M
2.84%
-1.22M
-28.66%
Dec 31, 2025
AXA Investment Managers UK Ltd.
2.77M
2.6%
--
--
Dec 31, 2025
Geode Capital Management, L.L.C.
2.52M
2.36%
-41.34K
-1.62%
Dec 31, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.6%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.6%
iShares Micro-Cap ETF
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
Avantis US Small Cap Equity ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI